New Data Validate Amicus’s Pompe Disease Candidate
- Amicus announced additional positive data from its phase 1/2 study in Pompe disease.
- The data confirm the potential of ATB200/AT2221 to become the new standard of care in Pompe disease.
- Increasing my price target to $17 based due to the addition of the Pompe combo to my model.
Amicus Therapeutics (NASDAQ:FOLD) reported additional positive data from its Pompe disease phase 1/2 study in May. I wrote about this candidate and its potential of becoming the new standard of care for Pompe disease earlier this year, based on its preclinical profile and early clinical data (the article is exclusive to Growth Stock Forum subscribers). The data Amicus reported last month further support that notion and I am increasing my price target on Amicus from $14 to $17 as I incorporate ATB200/AT2221 into my model.
Click here to read more.